Growth-related oncogene (GRO), a member of the CXC chemokine subfamily, plays a major role in inflammation and wound healing. CXC chemokines have been found to be associated with tumorigenesis, angiogenesis, and metastasis. Although elevated expression of GRO has been reported in several human cancers, the expression and role of GRO and its receptor, CXCR2, in esophageal cancer are poorly understood. This study used real-time reverse transcription-PCR (RT-PCR) and immunohistochemical approaches to show that GROA, GROB, and CXCR2 are up-regulated in esophageal tumor tissue. Furthermore, GROA, GROB, and CXCR2 are constitutively expressed in WHCO1, an esophageal cancer cell line that was used as a model system here. GROB enhances transcription of EGR-1, via the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, which can be blocked by a specific antagonist of CXCR2 (SB 225002) or specific antibody to GROB. WHCO1 cells treated with SB 225002 exhibited a 40% reduction in cell proliferation. A stable WHCO1 GROA RNA interference (RNAi) clone displayed a 43% reduction in GROA mRNA levels as determined by real-time RT-PCR, reduced levels of GROA by fluorescence microscopy, and a 60% reduction in the levels of phosphorylated ERK1/2. A stable clone expressing GROB RNAi displayed >95% reduction in GROB mRNA levels, reduced levels of GROB by fluorescence microscopy, and an 80% reduction in the levels of phosphorylated ERK1/2. Moreover, these GROA RNAi-and GROB RNAiexpressing clones displayed a 20% and 50% decrease in cell proliferation, respectively. Our results suggest that GROA-CXCR2 and GROB-CXCR2 signaling contributes significantly to esophageal cancer cell proliferation and that this autocrine signaling pathway may be involved in esophageal tumorigenesis. (Cancer Res 2006; 66(6): 3071-7) 
Introduction
A high incidence of esophageal squamous cell carcinoma has been reported in certain regions of the developing world, such as parts of Southeastern Africa, Iraq, South America, and China (1, 2) . In South Africa, esophageal squamous cell carcinoma occurs with a high frequency (ASR 12.60/100,000 in males and 5.58/100,000 in females) and is one of the most common causes of cancer-related mortality in Black males (3) . Despite the high mortality associated with this disease, the molecular events involved in the development of esophageal squamous cell carcinoma remain poorly understood. A better understanding of the molecular events involved in the development of esophageal squamous cell carcinoma may offer opportunities to identify diagnostic markers, therapeutic targets, or prognostic indicators for this disease. Using cDNA microarray analysis to identify genes potentially involved in the development of esophageal squamous cell carcinoma, we showed that primary esophageal tumor tissues expressed elevated levels of the chemokines growth-related oncogene (GRO)a and GROh, relative to adjacent normal tissues. 2 Chemokines are a superfamily of small, cytokine-like proteins that selectively regulate the recruitment and trafficking of leukocyte subsets to inflammatory sites through chemoattraction (4) . Members in this family have been divided into two major subfamilies, CXC and CC, based on the arrangement of the first two of the four conserved cysteine residues in the amino terminus of the proteins. The two cysteines are separated by a nonconserved amino acid in CXC chemokines and adjacent to each other in CC chemokines. Depending on the presence or absence of an ELR motif (Glu-Leu-Arg) immediately preceding the first cysteine, CXC chemokines are further subdivided into two groups, ELR+ CXC chemokines and ELRÀ CXC chemokines. ELR+ CXC chemokines, which are potent promoters of angiogenesis and bind to CXC chemokine receptor 1 or 2 (CXCR1 or CXCR2), include the GROs (GROa, GROh, and GROg), interleukin-8 (IL-8), epithelial-neutrophil activating protein (ENA-78), granulocyte chemotactic protein (GCP-2), neutrophil-activating protein (NAP-2), and h-thromboglobulin (5-7). ELRÀ CXC chemokines are potent inhibitors of the ELR+ CXC chemokine-mediated angiogenesis (6) , and include monokine induced by IFN-g (MIG), stromal cell-derived factor (SDF-1), IFN-g-inducible protein (IP-10), and platelet factor 4 (PF4; ref. 6 ). IP-10 and MIG bind to CXCR3 receptors, whereas SDF-1 only binds to the CXCR4 receptor (5) . The biological functions of ELR+ CXC chemokines are primarily mediated via CXCR2, a 7-transmembrane G-protein coupled receptor. Signaling for this receptor is mediated via various signaling pathways, including the extracellular signal-regulated kinases (ERK; refs. 8, 9) .
A large body of evidence indicates that CXC chemokines play a critical role in inflammatory reactions and wound healing (reviewed in ref. 10) . Additional evidence suggests that certain chemokines are involved in tumorigenesis because a wide range of cancers express elevated levels of various chemokines, such as IL-8 in non-small cell lung carcinoma and gastric carcinomas (11) (12) (13) , and GROa in melanoma and prostate cancer cells (14, 15) . In melanoma cells, GROa acts as an autocrine/paracrine growth factor because these cells express both GROa and its receptor, CXCR2 (16, 17) . IL-8 also functions as an autocrine growth factor in malignant melanoma cells (18) and other neoplasias, such as gastric (19) , hepatic, and pancreatic cancers (20) . Compared with GROa and IL-8, less is known about the role of GROh in tumorigenesis, although reports have implicated GROh in enhanced tumor growth of immortalized melanocytes (21) .
Presently, the expression status and role of GROa and GROh in esophageal squamous cell carcinoma is unknown. We therefore examined the expression of these two chemokines and their receptor, CXCR2, in esophageal squamous cell carcinoma tissues and adjacent normal tissues. Our results show that tumor tissues overexpress GROa, GROh, and CXCR2 compared with adjacent normal esophageal epithelial tissue, and, furthermore, that the esophageal squamous cell carcinoma cell lines WHCO1, WHCO5, and WHCO6 coexpress GROa, GROh, and CXCR2. An antagonist of CXCR2 (SB 225002) reduced proliferation of WHCO1 cells, and knockdown of GROa and GROh in WHCO1 cells using RNA interference (RNAi) reduced cell proliferation by 20% and 50%, respectively. These results implicate GRO and CXCR2 in a proliferative autocrine loop in esophageal squamous cell carcinoma cells.
Materials and Methods
Northern blot analysis. Total RNA was isolated from WHCO1 treated with 200 ng/mL anti-GROh for the indicated times using TRIzol (Invitrogen Corporation, Carlsbad, CA) according to the instructions of the manufacturer. Northern blot analysis was done as described (22) using 5 Ag total RNA. The nylon membranes containing transferred RNA were hybridized at 42jC in ULTRAhyb Ultrasensitive Hybridization Buffer (Ambion, Inc., Austin, TX) with the indicated probes (see below) labeled with [a-32 P]dCTP using the Megaprime DNA labeling system (Amersham Pharmacia Biotech UK Limited, Little Chalfont, Bucks, United Kingdom). The membrane was stripped and rehybridized with a b-actin probe to control for RNA loading. The probes included a 0.56 kb EcoRI fragment of EGR-1 cDNA and a 0.63 kb EcoRI fragment of b-actin cDNA. After scanning the membranes using a phosphoimager, the membranes were exposed to X-ray film.
Real-time reverse transcription-PCR and reverse transcription-PCR. Total RNA was prepared from four paired normal and esophageal squamous cell carcinoma biopsies and esophageal squamous cell carcinoma cultured cells using TRIzol (Invitrogen) according to the instructions of the manufacturer and quantified using UV absorbance at 260 nm (DU650 spectrophotometer, Beckman Instrument, Inc., Fullerton, CA). cDNA was synthesized using 5 Ag total RNA and oligo(dT) 20 primer using the SuperScript III system for reverse transcription-PCR (RT-PCR; Invitrogen) following the instructions of the manufacturer. Target primers for amplifying GROa, GROb, and CXCR2 were designed using Primer Designer (Scientific & Educational Software Version 2.0). GROa forward primer: 5V-ACCTCCTCGCCAGCTCTT-3V and reverse primer: 5V-CTTCAGGAACAGC-CACCAG-3V; GROb forward primer: 5V-AGCTCTCCTCCTCGCACA-3V and reverse primer: 5V-CTTCAGGAACAGCCACCAA-3V; CXCR2 forward primer: 5V-CTCCAATAACAGCAGGTCAC-3Vand reverse primer: 5V-GGCTCAGCAG-GAATACCA-3V. Each 50 AL reaction mixture for RT-PCR contained 2.5 mmol/L MgCl 2 , 0.5 Amol/L of each primer. Each 20 AL reaction mixture for real-time RT-PCR contained 2.5 mmol/L MgCl 2 , 0.5 Amol/L of each primer, and 1 AL LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics South Africa, Randburg, Gauteng, South Africa). RT-PCR analysis was done using GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA) and real-time RT-PCR analysis was carried out with LightCycler II (Roche Diagnostics GmbH, Mannheim, Germany). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as internal control to standardize and to test the RNA integrity. All experiments for real-time RT-PCR were done in triplicate, data was analyzed using the comparative C t method, and results are shown as fold induction of mRNA.
Immunohistochemical analysis. Samples for immunohistochemical analysis were sectioned from archived, paraffin-embedded normal and tumor tissues obtained from esophageal cancer patients who had undergone esophagectomies. The dewaxed slides were incubated with 1:20 dilution of normal rabbit serum ( for GROa and GROh, DakoCytomation Denmark A/S, Glostrup, Denmark) or normal goat serum ( for CXCR2, DakoCytomation Denmark) for 30 minutes and then incubated with 1:50 dilution of anti-GROa polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 1:100 dilution of anti-GROh polyclonal antibody (Santa Cruz Biotechnology) and 1:1,000 dilution of rabbit anti-human CXCR2 polyclonal antibody (a gift from Prof. Ann Richmond), respectively, at 4jC overnight. After rinsing in PBS, slides were incubated with 1:400 dilution of donkey anti-goat horseradish peroxidase ( for GROa and GROh, DakoCytomation Denmark) or DAKO(R) EnVision+ peroxidase ( for CXCR2, DakoCytomation Denmark) at room temperature for 30 minutes, and the color was developed using 3,3V-diaminobenzidine (DakoCytomation Denmark). Counterstaining was done with hematoxylin. The stained tissue sections were analyzed independently by two pathologists.
Cell culture. Three esophageal squamous cell carcinoma cell lines WHCO1, WHCO5, and WHCO6 originally established from surgical biopsies of primary esophageal squamous cell carcinomas (23) were cultured in DMEM containing 10% FCS at 37jC in a humidified atmosphere of 5% CO 2 . 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were carried out using the Cell Proliferation kit I (Roche Diagnostics South Africa) as described by the manufacturer. Briefly, 1.5 Â 10 3 cells were plated in 96-well plates in a final volume of 180 AL DMEM per well. SB 225002 (antagonist of CXCR2, 400 nmol/L, Calbiochem, Darmstadt, Germany) was added to cells and 0.001% DMSO (solvent) was added as a control. After the indicated incubation period, 18 AL of the MTT labeling reagent ( final concentration 0.5 mg/mL) was added to each well and incubated for 4 hours in a humidified atmosphere. One hundred eighty microliters of the solubilization solution were added to each well and the plates were left overnight at 37jC. The spectrophotometric absorbance of samples was measured at 595 nm using a microtiter plate reader.
Inhibition of CXCR2 activity. CXCR2 function was inhibited with either a specific antagonist (SB 225002) or GRO antibodies. For treatment with SB 225002, WHCO1 cells were plated at 1.5 Â 10 5 per well in 2 mL DMEM in a six-well plate. Twenty-four hours later, the medium was changed, SB 225002 was added into the medium to the final concentrations of 25, 50, 100, 200, 400, and 800 nmol/L, and 0.001% DMSO was used as solvent control. Cells were incubated at 37jC for a further 48 hours. For treatment with antibodies, WHCO1 cells were plated into six-well plates at 1 Â 10 5 per well. Three days later, GROa antibody or GROh antibody was added to the indicated concentration and incubated for the indicated times.
Western blot analysis. Treated WHCO1 cells were rinsed twice with icecold PBS and scraped off the plate in radioimmunoprecipitation assay buffer [150 mmol/L NaCl, 1% Triton X-100, 0.1% SDS, 25 mmol/L Tris-Cl (pH 7.5), 1% sodium deoxycholate, 20 Ag/mL pepstatin, 5 Ag/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride], sonicated for 5 seconds on ice with a probe sonicator (Heat System-Ultrasonics, Inc., Plainview, NY), and centrifuged for 10 minutes at 13,000 Â g in a microcentrifuge. The protein concentration of the lysates was determined using the BCA Protein Assay kit (Pierce, Rockford, IL). Fifteen micrograms protein per sample was electrophoresed on 10% SDS-PAGE and electrophoretically transferred to nitrocellulose membrane (Hybond-ECL, Amersham Pharmacia Biotech UK) at 4jC for 1.5 hours. Blots were incubated for 1 hour with 5% nonfat dry milk to block nonspecific binding sites and then incubated with goat polyclonal antibody against phosphorylated ERK1/2 (Santa Cruz Biotechnology) at 4jC overnight. The immunoreactivity was detected using peroxidase-conjugated antibody and visualized by enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Pierce). The blots were stripped before reprobing with antibody to ERK2 (Santa Cruz Biotechnology).
RNA interference. To create the small interfering RNA (siRNA) plasmid constructs, complementary strands of oligonucleotides specifically targeting GROa and GROh were synthesized. For GROa siRNA, oligo1: 5V-CTGTTTAGATGAATGTCAGTTCAAGAGACTGACATTCATCTAAA-CAGTTTTTT-3V, oligo2: 5V-AATTAAAAAACTGTTTAGATGAATGT-CAGTCTCTTGAACTGACATTCATCTAAACAGGGCC-3V; for GROh siRNA, oligo1: 5V -TCTACTTGCACACTCTCCCTTCAAGAGAGGGAGAGTGTGC-AAGTAGATTTTTT-3V , oligo2: 5V -AATTAAAAAATCTACTTGCACACT-CTCCCTCTCTTGAAGGGAGAGTGTGCAAGTAGAGGCC-3V . After annealing, double-stranded oligonucleotides were cloned into ApaI and EcoRI linearized pSilencer 1.0-U6 vector (Ambion). The insert, together with U6 promoter, was released by NotI and KpnI digestion. The cytomegalovirus promoter in pcDNA 3.1(+) vector was released with NotI and MulI digestion and replaced with the U6 promoter/oligonucleotide insert and a linker to obtain pcDNA3.1-U6/GROaRNAi and pcDNA3.1-U6/GROhRNAi. The inserts were confirmed by DNA sequence analysis. The U6 promoter-driven siRNAs express the sense and antisense strands of GROa or GROh siRNA that have a termination signal consisting of six thymidines.
Transfection and immunofluorescence. Stable transfection of WHCO1 cells with either pcDNA3.1-U6/GROaRNAi or pcDNA3.1-U6/GROaRNAi or pcDNA3.1-U6 (empty vector) using FuGENE 6 Transfection Reagent (Roche Diagnostics South Africa) was carried out as recommended by the manufacturer.
To detect the expression level of GROa or GROh in positive clones selected by G418, immunofluorescence staining was done. Briefly, cells were cultured on coverslips, fixed, and permeabilized with methanol and 4% paraformaldehyde, then incubated with 1:50 dilution of goat anti-GROa polyclonal antibody (Santa Cruz Biotechnology) or with 1:100 dilution of goat anti-GROh polyclonal antibody (Santa Cruz Biotechnology) in blocking buffer at 4jC overnight. After incubation with primary antibody, cells were washed five times in PBS (pH7.4) and incubated with 1:100 dilution of FITCconjugated rabbit anti-goat antibody (Zymed Laboratories, Inc., South San Francisco, CA) for 2 hours at room temperature. After five washes in PBS, nuclei were stained with 4V,6-diamidino-2-phenylindole (DAPI; SigmaAldrich South Africa Ltd., Aston Manor, South Africa). Fluorescence was observed by using a Â40 objective lens on an inverted microscope (Zeiss Axiovert 200 M, Jena, Germany). The specificity of the antibodies was tested using specific blocking peptides for either anti-GROa or anti-GROh using immunofluorescence staining.
Statistical analysis. The Student's t test was used for statistical significance of differences in the expression of GROa, GROh, and CXCR2 between groups. P < 0.05 was considered to be significant.
Results
Overexpression of GROA, GROB, and CXCR2 in esophageal squamous cell carcinoma. An initial study using cDNA microarray analysis indicated that both GROa and GROh were overexpressed by 1.7-fold in esophageal squamous cell carcinoma biopsies compared with adjacent normal tissue from the same individual (data not shown). Because the cDNA microarray was done with pooled RNA from three patients, using reciprocal labeling, further analysis was carried out to verify the difference in GROa and GROh expression between normal and tumor esophageal tissue. Specific primers were designed to quantitate GROa and GROh mRNA levels in tissue, and the PCR products generated (423 and 409 bp for GROa and GROh, respectively; Fig. 1A ) were sequenced to verify their identity. Real-time RT-PCR using total RNA isolated from esophageal squamous cell carcinoma and adjacent normal tissues confirmed that GROa was indeed overexpressed (by 2-fold to 5-fold, P < 0.05) in all four of the esophageal tumor tissues analyzed (Fig. 1B) . Similarly, GROh mRNA levels were also overexpressed (by 1.5-8 fold, P < 0.05) in three of the four esophageal tumor tissues examined, relative to adjacent normal tissue (Fig. 1C) . To establish whether GROa and GROh could potentially function as autocrine signaling molecules in esophageal squamous cell carcinomas, we determined the expression of CXCR2 (a receptor for GROa and GROh) in the same tissues. CXCR2 mRNA levels were also overexpressed (by 1.6-20 fold, P < 0.05) in the tumor tissues examined (Fig. 1D) . To verify the expression of these two chemokines and their receptor, CXCR2, immunohistochemical analysis was done using esophageal tumor and matched normal tissue sections obtained from esophageal cancer patients that had undergone esophagectomies. The immunohistochemical analysis showed that GROa was overexpressed in 7 of 10 tumor sections analyzed, and that GROh was overexpressed in 11 of 14 tumor sections examined ( Fig. 2A-D) . These results confirmed that both GROa and GROh were overexpressed in esophageal tumor tissue, and, furthermore, that these two chemokines were primarily located in the cytoplasm ( Fig. 2A-D) . CXCR2 levels were elevated in 88% of tumor sections examined (n = 65), whereas it was either absent or was present at very low levels in matched normal tissue Figure 1 . Expression of GROa, GROh, and CXCR2 in esophageal normal and tumor tissues. Total RNA was extracted from biopsies (normal and tumor tissue) obtained from patients diagnosed with esophageal squamous cell carcinoma. The total RNA was subjected to RT-PCR, and the PCR products were analyzed by agarose gel electrophoresis (A, lane 1, DNA molecular weight marker VIII; lane 2, GROa RT-PCR product; lane 3, GROh RT-PCR product; lane 4, CXCR2 RT-PCR product). Real-time RT-PCR was also carried out with GROa-, GROh-, and CXCR2-specific primers (B-D ). Columns, ratio of GROa, GROh, and CXCR2 mRNA relative to GAPDH in esophageal squamous cell carcinoma tumor samples and normal esophageal samples; bars, SD of each sample measured in triplicate.
( Fig. 2E and F) . Our results also showed that the CXCR2 receptor was localized in the plasma membrane and cytoplasm of the cells examined. These findings demonstrating that esophageal squamous cell carcinomas coexpress GROa, GROh, and CXCR2, and suggest that these chemokines could play an autocrine role in this poorly understood cancer.
Expression of GROA, GROB, and CXCR2 in cultured esophageal cancer cell lines. Three cultured esophageal cancer lines (WHCO1, WHCO5, and WHCO6) were tested to identify a model system in which the role of CXCR2 and its ligands (GROa and GROh) could be explored in esophageal squamous cell carcinoma. RT-PCR analysis using total RNA isolated from the three cell lines revealed that GROa, GROh, and CXCR2 were expressed in all three cell lines examined (Fig. 3) . WHCO1 was selected as a model system to further explore the role of CXCR2 and its ligands in esophageal cancer because this cell line constitutively expresses GROa, GROh, and CXCR2.
Transduction of GROB signal through the ERK1/2 pathway. Our next objective was to determine whether the observed expression of GROa, GROh, and CXCR2 in WHCO1 cells constituted a functional autocrine loop in these cultured cells. Because recent evidence indicated that GROa could signal via the ERK1/2 pathway (24), we treated WHCO1 cells with SB 225002 (a specific inhibitor of CXCR2; ref. 25, 26) , and measured levels of phosphorylated ERK1/2 in treated cells by Western blot analysis. Increasing concentrations of SB 225002 substantially reduced the levels of phosphorylated ERK1/2 in WHCO1 cells, leaving unphosphorylated ERK2 levels unaffected (Fig. 4A) . Densitometric analysis of the bands indicated that 100 nmol/L SB 225002 reduced p-ERK1/2 levels by 30%, similar to the IC 50 value of 88 nmol/L reported by Catusse et al. (26) . Although the results in Fig. 4A strongly suggest that the CXCR2 receptors are activated in WHCO1 cells (leading to phosphorylation of ERK1/2), the identity of the ligand/s responsible for activating CXCR2 is less clear. To address this question, WHCO1 cells were incubated with either anti-GROa or anti-GROh for the indicated times, followed by measurement of phosphorylated ERK1/2 levels. Treatment of WHCO1 cells with anti-GROh substantially reduced the amount of phosphorylated ERK1/2 in treated cells (Fig. 4B) . In contrast, treatment of WHCO1 cells with anti-GROa had no effect on the levels of phosphorylated ERK1/2 measured in the cell lysates, regardless of the time of exposure to the antibody (Fig. 4C) . As another marker of the functionality of the GROh/CXCR2 autocrine loop in WHCO1 cells, we also measured the effect of anti-GROh treatment on the expression of EGR-1 mRNA because previous reports have identified EGR-1 as a downstream target of ERK1/2 signaling (27) (28) (29) . Depletion of GROh in the medium of WHCO1 cells (using anti-GROh) resulted in a time-dependent reduction of EGR-1 mRNA levels in treated cells (Fig. 5) . These results strongly Figure 2 . Immunohistochemical analysis of GROa, GROh, and CXCR2. Formalin-fixed, paraffin-embedded esophageal tumor tissues (B, D, F ) and adjacent normal tissues (A, C, E ) were subjected to immunohistochemical staining using polyclonal antibodies to human GROa (A, B) , GROh (C, D ), and CXCR2 (E, F ) as described in Materials and Methods. CXC chemokines GROa and GROh are both located in the cytoplasm (see arrows in B and D , respectively), whereas their receptor, CXCR2, is located in the cytoplasm and membrane (arrow in F ). GROh also stained positively in some neutrophils (arrow in C ). Bar, 10 Am. b, basal cells of esophageal epithelium; m, mature epithelial cells; c, cytoplasmic staining; M+c, membrane and cytoplasm staining; n, neutrophils. Figure 3 . Expression of GROa, GROh, and CXCR2 in esophageal squamous cell carcinoma cell lines. Total RNA isolated from three esophageal squamous cell carcinoma cell lines, WHCO1, WHCO5, and WHCO6, was subjected to RT-PCR using specific primers for GROa, GROh, and CXCR2. An RT-PCR step using primers for GAPDH was included for each RNA sample to assess the quality of the isolated RNA. The PCR products were separated by agarose gel electrophoresis. Research.
suggested that GROh signals via the ERK1/2 pathway and constitutes an autocrine loop with CXCR2 in cultured WHCO1 cells.
Signaling through CXCR2 promotes proliferation of WHCO1 cells. Because it is known that GROa stimulates cell proliferation in melanoma cells through an autocrine loop (14, 16), we explored the possible contribution of the GROa/CXCR2 and GROh/CXCR2 loops to proliferation of WHCO1 cells. Blocking CXCR2 signaling in WHCO1 cells with 400 nm SB 225002 significantly decreased cell proliferation by f40% to 50% (Fig. 6) , suggesting that CXCR2-mediated signaling contributed substantially to proliferation of WHCO1 cells in culture.
However, this approach failed to differentiate between CXCR2 ligands secreted by WHCO1 cells and tissue culture serum-derived CXCR2 ligands. Furthermore, we could not exclude nonspecific effects of the antagonist (SB 225002) used at this concentration on cell proliferation. To address this problem, we used RNAi vectors to inhibit GROa and GROh expression in stably transfected WHCO1 cells. Using fluorescent immunocytochemistry, we showed that stably transfected WHCO1 cells containing siRNA against GROh expressed significantly lower levels of GROh than cells transfected with vector only (Fig. 7A, top) . Using commercially available competing ligands for GROa and GROh, we confirmed that >90% of the fluorescence signal observed for these antibodies was specific (data not shown). Real-time RT-PCR analysis confirmed >95% (P < 0.05) reduction in GROh mRNA levels in the GROh RNAi clone relative to the vector control (Fig. 7B, top) . Furthermore, the stably transfected clone expressing siRNA against GROh displayed an 80% reduction in phosphorylated ERK1/2 levels relative to control cells (Fig. 7C) , suggesting that secreted GROh contributed to the activation of this mitogen-activated protein kinase signaling pathway. Although WHCO1 cells stably transfected with pcDNA3.1-U6/GROaRNAi expressed lower levels of GROa (Fig. 7A, bottom) than control cells, the reduction in GROa expression was less substantial than the knockdown observed for GROh (Fig. 7A, top) . This was confirmed by real-time RT-PCR analysis that indicated that GROa mRNA levels had been knocked down by 50% (P < 0.05) in the GROa RNAi clone (relative to the vector control; Fig. 7B , bottom). The GROa RNAi clone only displayed a 60% reduction in the level of phosphorylated ERK1/2 relative to control cells (Fig. 7C) . Reducing GROh expression levels in WHCO1 cells with GROh RNAi reduced the proliferation rate of these cells by f50% relative to wild-type or the vector control WHCO1 cells (Fig. 8) . WHCO1 cells stably transfected with GROa RNAi, however, displayed a 20% reduction in cell proliferation relative to vector control cells (Fig. 8) . Cell cycle analysis by flow cytometry suggested that the reduced proliferation of GROa-RNAi and GROh-RNAi-expressing stable clones of WHCO1 was not due to severe disruption of the cell cycle or cell cycle block because GROaRNAi and GROh-RNAi-expressing clones displayed cell cycle profiles similar to wild-type and vector control cells (data not shown).
Discussion
Hanahann and Weinberg (30) identified six biological characteristics that cells acquire en route in their transformation to cancer. One of these highlights the ability of cancer cells to lose their dependence on surrounding cells for proliferative signals, and, instead, to resort to alternative proliferative signals that facilitate unregulated growth. The results of this study suggest that esophageal Figure 4 . Phosphorylated ERK1/2 in response to treatment with SB 225002, anti-GROa, and anti-GROh antibodies. WHCO1 whole cell lysates were prepared at the indicated times after treatment with various concentrations of SB 225002 (A ), 200 ng/mL anti-GROh (B), and 200 ng/mL anti-GROa (C). Proteins were resolved on 10% SDS-PAGE and transferred to Hybond ECL (see Materials and Methods). The level of phosphorylated ERK1/2 was detected using a polyclonal antibody specific for phosphorylated ERK1/2. Levels of unphosphorylated ERK2 were used as a loading control. U, untreated cells. Figure 5 . Expression of EGR-1 in WHCO1 cells treated with anti-GROh. Total cellular RNA was isolated from WHCO1 cells treated with 200 ng/mL anti-GROh for the indicated times. Northern blot analysis was done using a cDNA probe to EGR-1, whereas h-actin was used as a loading control as described in Materials and Methods. WHCO1 cells grown in 96-well plates were treated with either 400 nmol/L SB 225002 or 0.001% DMSO as a solvent control for the indicated times. The MTT assay was done as described in Materials and Methods and the absorbance was detected at 595 nm using a microtiter plate reader. Each point was done in quadruplicate, and the experiment was done twice.
squamous cell carcinoma cells express the functional autocrine loop involving GROa, GROh, and their receptor, CXCR2, which contributes substantially to the proliferation of esophageal cancer cells in culture. The immunohistochemical evidence presented here suggests that the GROa/CXCR2 and GROh/CXCR2 chemokine loop probably contributes to proliferation in most primary esophageal squamous cell carcinoma tissues in situ. Recent studies have shown an increasingly important role of chemokines in the biology of a wide array of cell types, including cancer cells, in addition to their role in regulating directional migration of leukocytes during inflammatory responses (31) . Although this is the first description of a proliferative chemokine autocrine loop operating in esophageal cancer, other studies have implicated GROa and IL-8 in the progression of malignant melanoma, hepatic cancer, and pancreatic cancer via an autocrine loop involving CXCR2 (14, (16) (17) (18) 20) .
Although the GROh/CXCR2 chemokine loop clearly contributes to proliferation in WHCO1 cells, the role of GROa in these cells is less obvious, despite our demonstration that esophageal cancer cells express both GROa and GROh (by immunohistochemistry and RT-PCR) and other studies showing that CXCR2 binds both GROa and GROh (9) .
The modest reduction (20%) in cell proliferation observed in a GROa knockdown clone (Fig. 8) probably reflect an incomplete knockdown of GROa mRNA levels because fluorescent microscopy revealed a larger knockdown effect on GROh than GROa. The realtime RT-PCR results (Fig. 7B ) also confirm that GROa was incompletely knocked down. Although only a 20% reduction of cell proliferation was observed in the GROa knockdown clone, our results still suggest that GROa signaling is mediated through ERK1/2, because a 60% reduction in phosphorylated ERK1/2 was shown in this clone. The apparent inability of anti-GROa treatment to reduce phosphorylated ERK1/2 levels in WHCO1 cells (Fig. 4C) could reflect the inability of the GROa antibody to remove secreted GROa from the culture medium.
Using cultured esophageal cancer cells as a model system, our results clearly suggest that GROh signaling is also mediated through ERK1/2, and that blocking GROh (either with an antibody, CXCR2 antagonist or RNAi) substantially reduced signaling through ERK1/ 2. This is consistent with previous evidence indicating that CXCR2 can signal through ERK1/2 in addition to other pathways (24) . We also showed that GROh makes a major contribution to the elevated transcription of EGR-1 in cultured esophageal cancer cells. Preliminary immunohistochemical results obtained in our laboratory Figure 7 . RNAi mediated GROa and GROh knockdown in WHCO1 cells. To selectively knock down GROa and GROh, WHCO1 cells were stably transfected with either pcDNA3.1-U6/GROaRNAi or pcDNA3.1-U6/GROhRNAi and selected with G418. Cells were grown on coverslips and the immunofluorescence staining of GROh in the clone expressing GROh RNAi (A, top ) and GROa in the clone expressing GROa RNAi (A, bottom ) was done as described in Materials and Methods. Nuclei were visualized using DAPI. Magnification, Â400. cDNA synthesized from RNA extracted from these clones was subjected to real-time RT-PCR using GROa-specific and GROh-specific primers (B), whereas the levels of phosphorylated ERK1/2 were detected by Western blot using a specific antibody to phosphorylated ERK1/2 (C ). Figure 8 . Proliferation of WHCO1 cells transfected with either pcDNA3.1-U6/ GROaRNAi or pcDNA3.1-U6/GROhRNAi. To determine the effect of GROh-RNAi and GROa-RNAi silencing on the proliferation of WHCO1 cells, the MTT assay was done as described in Materials and Methods and the absorbance measured at 595 nm using a microtiter plate reader.
show that EGR-1 is significantly overexpressed in esophageal squamous cell carcinoma tissue compared with normal esophageal squamous epithelial tissue. The relationship between GROh and EGR-1 expression in esophageal cancer is presently being explored further in our laboratory. The implications of the relationship between GROh and EGR-1 are very significant because EGR-1 is known to regulate the expression of many genes involved in tumorigenesis, including insulin-like growth factor-II (32, 33) and vascular endothelial growth factor (34) .
Because ELR-containing chemokines, such as GROh, GROa, and IL-8, are potent angiogenic factors (8), our observation that esophageal squamous cell carcinoma cells secrete GRO may facilitate the gain in these cells of yet another important phenotypic hallmark of cancer (30) . In this context, the GROa/CXCR2 and GROh/CXCR2 loops may play an important role in the development and maintenance of squamous esophageal cancer, and consequently this chemokine system represents a significant therapeutic target that should be considered in the future treatment of esophageal cancer. Approaches targeting chemokine systems in other cancers have already shown considerable promise. A small molecular inhibitor of CXCR4 (AMD3100) reduced proliferation and induced apoptosis of intracranial xenograft brain tumors in mouse model studies (35) . Progress made in the development of orally bioavailable, potent antagonists of CXCR2 (36) suggest that clinicians may soon have at their disposal a range of small molecule antagonists of CXCR2. The results of the present study (showing reduced proliferation of cultured cancer cells in response to CXCR2 antagonist or RNAi treatment) have highlighted the feasibility of disrupting the GROh/CXCR2 loop as a treatment strategy in squamous esophageal cancer. Studies showing that mouse gene knockouts of CXCR2 display minimal pathology (37) suggest that this treatment route warrants further investigation, despite the pleiotropic effects of chemokine systems.
